A US team successfully delivered the glutamic acid dehydroxylase (GAD) gene (enzyme replacement) with an AAV2 vector to the STN of PD patients in both Phase I and II trials, and has shown significant efficacy in peer-reviewed publications [89,90], prompting discussions of proceeding to a more definitive Phase III trial. Here, GAD1 is linked to Parkinson disease.